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ABSTRACT   
Objective: Mutations in TPM3, encoding Tpm3.12, cause a clinically and histopathologically diverse group of 
myopathies characterized by muscle weakness. We report two patients with novel de novo Tpm3.12 single glutamic acid 
deletions at positions ΔE218 and ΔE224, resulting in a significant hypercontractile phenotype with congenital muscle 
stiffness, rather than weakness, and respiratory failure in one case. 
Methods: The effect of the Tpm3.12 deletions on the contractile properties in dissected patient myofibers was measured. 
We used quantitative in vitro motility assay (IVMA) to measure Ca2+-sensitivity of thin filaments reconstituted with 
recombinant Tpm3.12 ∆E218 and ∆E224.  
Results: Contractility studies on permeabilized myofibers demonstrated reduced maximal active tension from both 
patients with increased Ca2+ sensitivity with altered cross-bridge cycling kinetics in ΔE224 fibers. In vitro motility 
studies showed a two-fold increase in Ca2+-sensitivity of the fraction of filaments motile and the filament sliding velocity 
concentrations for both mutations.   
Interpretation: This data indicates that Tpm3.12 deletions ΔE218 and ΔE224 result in increased Ca2+ sensitivity of the 
troponin-tropomyosin complex, resulting in abnormally active interaction of actin and myosin complex. Both mutations 
are located in the charged motifs of the actin-binding residues of tropomyosin 3, thus disrupting the electrostatic 
interactions that facilitate accurate tropomyosin binding with actin necessary to prevent the on-state. The mutations 
destabilize the off-state and result in excessively sensitized excitation-contraction coupling of the contractile apparatus. 
This work expands the phenotypic spectrum of TPM3-related disease and provides insights into the pathophysiological 
mechanisms of the actin-tropomyosin complex.  
 
 
INTRODUCTION  
Tropomyosin 3, Tpm3.12,  (α-tropomyosin slow) encoded by the TPM3 gene (OMIM 191030), belongs to the 
actin-binding tropomyosin family and is a component of the sarcomeric thin filament troponin-tropomyosin complex. 
Tpm3.12 is predominantly expressedin type 1 (slow twitch) fibers and forms dimers of linear coiled-coil structures with 
Tpm2.2 (β-tropomyosin) encoded by TPM2 and Tpm1.1 (α-tropomyosin) encoded by TPM1, which then bind head-to-
tail providing structural stability to actin filaments.1,2 This complex acts by regulating Ca2+- dependent binding of the 
myosin head to the actin filament. It is an essential component in the regulation of muscle contraction by preventing 
binding of the myosin head when in the off-state and allowing it in the on-state, in preparation for the force generating 
power stroke. Mutations in TPM3 recognized thus far result in a clinically and histopathologically heterogeneous group 
of neuromuscular disorders, characterized by progressive weakness and include cap myopathy,3–5 congenital fiber type 
disproportion (CFTD),6 and autosomal dominant as well as recessive nemaline myopathy,7–10.  
Mutations in TPM2 also typically result in a phenotype of myopathy, manifesting with weakness. However, the 
deletion of a single lysine residue at position 7 in Tpm2.2 can manifest clinically with both muscle weakness and 
moderate progressive muscle contractures. Studies of this specific mutation suggest that the pathogenic mechanism 
underlying some tropomyosin-related disease may be due to elevated Ca2+ sensitivity of the contractile apparatus.11,12 
While such a mechanism had been predicted on theoretical molecular grounds to also be applicable for Tpm3.12,13 this 
phenomenon had not yet been shown conclusively to be clinically relevant for Tpm3.12. 11,12 
Here we report two unrelated patients with two distinct but closely spaced de novo Tpm3.12 single glutamic 
acid deletions resulting in a marked generalized hypercontractile phenotype with very significant congenital muscle 
stiffness, in the absence of detectable weakness, and associated with respiratory failure in the more severely affected 
patient. The effect of the Tpm3.12 glutamic acid deletions was studied using in vitro motility assays and mechanics on 
permeabilized myofibers, and these deletions appear to result in impaired maximum force generation with altered cross-
bridge cycling kinetics, and increased Ca2+ sensitivity of force. This study expands the clinical, phenotypic, and 
pathophysiological spectrum of TPM3 mutations, which now join a specific ACTA1 mutation as well as recessive αβ-
crystallin (CRYAB) mutations as a myogenic cause for significant neonatal muscle rigidity.14,15 
  
SUBJECTS/MATERIALS AND METHODS 
Patient recruitment & sample collection 
Two unrelated patients, one from the United States and one from Germany, were identified through their local 
neurologists. Medical history was obtained and clinical evaluations were performed as part of the standard neurologic 
evaluation. This study was approved by the Institutional Review Board of the National Institute of Neurological 
Disorders and Stroke, National Institutes of Health (NIH). Written informed consent was obtained from each family by a 
qualified investigator. DNA was obtained from blood based on standard procedures. Muscle biopsies were obtained as 
part of the regular clinical diagnostic testing and were evaluated by standard light and electron microscopic protocols. 
Banked muscle biopsy samples were transferred to the NIH for further analysis. 
 
Genetic testing 
Whole exome sequencing on blood samples obtained from Patient 1 (P1) and his parents was performed at the 
NIH Intramural Sequencing Center (NISC) using Illumina's TruSeq Exome Enrichment Kit and Illumina HiSeq 2000 
sequencing instruments. Mutations were analyzed using GEM.app and x-browse and searched for in dbSNP, NHLBI 
EVS, Exac Browser or GEM.app.16 PCR amplification of exon 6 of TPM3 in P1, Patient 2 (P2), and their parents, was 
followed by Sanger sequencing on an ABI 3130x1 capillary sequencer, in forward and reverse direction.  
 
Synthesis of tropomyosin in SF9 insect cells  
The wildtype human TPM3 cDNA sequence was amplified from reverse transcribed skeletal muscle RNA and 
then cloned into the BacPak8 plasmid (Clontech). The ΔE218 and ΔE224 mutations were introduced into the TPM3 
cDNA by site-directed mutagenesis. The wildtype and two mutant tropomyosin proteins were expressed in Sf9 insect 
cells using the flashBAC baculovirus system (Oxford Expression Technologies). Recombinant proteins were purified 
using protocols based on Akkari et al. 2002.17 
 
Quantitative in vitro motility assay 
Thin filaments were reconstituted with 10nM rabbit skeletal muscle α-actin (labeled with TRITC phalloidin),18  
tropomyosin (40-60nM) and skeletal troponin (60nM) to study Ca2+-regulation of filament motility by the quantitative in 
vitro motility assay previously described.19,20 Thin filament movement over a bed of immobilized rabbit fast skeletal 
muscle heavy meromyosin (100 µg/ml) was then compared inpaired motility cells with wild type or mutant tropomyosin. 
Filament movement was recorded and analyzed as previously described,19 yielding two parameters, the fraction of 
filaments moving and the speed of moving filaments. Fraction motile and sliding speed was measured over a range of 
Ca2+ concentrations to generate Ca2+-activation curves as shown previously.20–23 The temperature was set to 29 °C. EC50 
values from replicate experiments were analyzed by paired t-test since EC50 has been shown to be normally 
distributed.20,24  
 
Permeabilized myofiber contractile performance  
The effect of the Tpm3.12 deletion on the contractile properties in myofibers derived from patients’ muscle 
biopsies were measured. Myofiber bundles from frozen muscle biopsies from P1 and P2 and age-matched controls were 
isolated as described previously.13,25,26 In brief, smaller sections (2x2mm) of the biopsies were isolated in liquid nitrogen. 
They were then placed for 24h at -20°C in 4 mL 50% glycerol/relaxing solution containing high concentrations of 
protease inhibitors [phenylmethylsulfonyl fluoride (PMSF), 0.5mM; leupeptin, 0.04mM; E64, 0.01mM]. Subsequently, 
the sections were placed on a ‘roller band’ for 24h at 4°C, followed by submersion in skinning solution for 24h at 4°C. 
Finally, the skinning solution was substituted by a glycerol/relaxing solution with lower concentrations of protease 
inhibitors and stored at -20°C until further use. On the day of an experiment, small strips (CSA 0.005~0.01 mm2) were 
dissected from the glycerinated sections and washed thoroughly with relaxing solution. The strips were mounted using 
aluminum T-clips between a length motor (ASI 403A, Aurora Scientific Inc., Ontario, Canada) and a force transducer 
element (ASI 315C-I, Aurora Scientific Inc., Ontario, Canada) in a skinned fiber apparatus (ASI 802D, Aurora Scientific 
Inc., Ontario, Canada) that is mounted on an inverted microscope (Zeiss Axio Observer A1). Sarcomere length (2.5 µm) 
was set using a high speed VSL camera and ASI 900B software (Aurora Scientific Inc., Ontario, Canada). Six strips 
were analyzed for P1 (average CSA 0.01 mm2), P2 (average CSA 0.005 mm2) and control (average CSA: 0.006 mm2). 
Fiber width and diameter was measured at three points along the fiber and the cross-sectional area (CSA) was 
determined assuming an elliptical cross-section. Fiber dimensions were determined using an inverted microscope (40x 
objective), a high-speed VSL camera with calibrated ASI 900B software (Aurora Scientific Inc., Ontario, Canada) and a 
custom-made prism that is mounted in the bath. Various types of bathing solutions were used during the experimental 
protocols: a relaxing solution (40 mM BES; 10 mM EGTA; 6.86 mM MgCl2; 5.96 mM Na-ATP; 3.28 mM K-
propionate; 33 mM creatine phosphate; 1 mM DTT; 0.5 mM PMSF; 0.2 mM Leupeptin; 0.05 mM E64), a pre-activating 
solution with low EGTA concentration (40 mM BES; 1 mM EGTA; 6.66 mM MgCl2; 5.98 mM Na-ATP; 30.44 mM K-
propionate; 33 mM creatine phosphate; 1 mM DTT; 0.5 mM PMSF; 0.2 mM Leupeptin; 0.05 mM E64), and activating 
solutions with incremental Ca2+ concentrations for graded Ca2+ response curves (40 mM BES; 10 mM CaCO3-EGTA 
(for maximal activation); 6.64 mM MgCl2; 6.23 mM Na-ATP; 2.1 mM K-propionate; 15 mM creatine phosphate; 1 mM 
DTT; 0.5 mM PMSF; 0.2 mM Leupeptin; 0.05 mM E64). The temperature of the bathing solutions was kept constant at 
20°C using a temperature controller (ASI 825A, Aurora Scientific Inc. Ontario, Canada).  
Absolute forces were normalized to the bundles’ CSA to determine the maximal active tension. To determine 
the Ca2+-sensitivity of force generation, permeabilized myofiber bundles were sequentially bathed in a relaxing solution, 
a pre-activation solution and solutions with pCa values ranging from 9.0 to 4.5. Steady-state forces were measured at all 
the Ca2+ concentrations, and subsequently these steady-state values were normalized to the maximal force obtained at 
pCa 4.5. The obtained force-pCa data were fit to the Hill equation [Y=1/(1+10nH(pCa−pCa50))]. Cross-bridge cycling 
kinetics were determined by imposing a rapid release-restretch protocol on an activated fiber based on previously 
reported methods.27 The rate of tension redevelopment was obtained by fitting a bi-exponential through the force 
redevelopment curve. The resulting first-order rate constant k1 reflects cross-bridge cycling kinetics and thus was used in 
the analyses methods.28 A measure of active stiffness was obtained by applying small length perturbations on the 
myofibers, while the myofibers were being maximally activated, and fit to a linear curve through the data points. By 
dividing the maximal active tension by active stiffness, the force generation per cross-bridge is estimated.29  
 
Myosin heavy chain isoform composition of myofibers used for contractility experiments 
Since the contractile performance of muscle fibers is affected by the composition of myosin heavy chain 
isoforms, we used specialized SDS-PAGE to determine the myosin heavy chain isoforms present in the muscle fibers 
used for contractile measurements.25 In brief, muscles fibers were denatured by boiling for 2 min. in SDS sample buffer. 
The stacking gelcontained a 4% acrylamide concentration (pH 6.7), and the separating gel contained 7% acrylamide (pH 
8.7) with 30% glycerol (v/v). The gels were run for 24h at 15°C and a constant voltage of 275V. Finally, the gels were 
silver-stained, scanned, and analyzed with One-D scan EX (Scanalytics Inc., Rockville, MD, USA) software (data not 
shown). 
  
RESULTS 
Clinical assessment identified two patients with a significant hypercontractile phenotype with marked 
congenital muscle stiffness.  
We identified two patients with a history of marked congenital muscle stiffness, which was most significant at 
the onset. Detailed clinical information is summarized in table 1, figure 1.  
Patient 1 (P1) is a 5-year old male. Pregnancy was notable for decreased fetal movements but normal amniotic 
fluid level. He was born with arthrogryposis multiplex congenita with bilateral contractures of the hips, knees, and 
wrists. He also had bilateral hand fisting, right clubfoot deformity, unilateral hip dislocation, an inguinal hernia and 
generalized muscle stiffness. Neonatal course was complicated by transient respiratory distress, particularly during 
feeding, manifesting with an increased respiratory rate.  He also had a history of low oxygen saturations and occasional 
grunting at rest as a neonate. He rolled from his back to his side at 6 months of age, could manipulate objects in his 
hands and bring some objects to his mouth by 15 months of age, and walked independently at 25 months of age. He had 
notable easy fatigability. 
On examination at age 4 years, he had a “wooden feel” to his muscles, which were noted to be very stiff, 
particularity the hamstrings, the paraspinal muscles and the face muscle. He had well-defined biceps and prominent thigh 
muscles. There was no muscle weakness noted. Deep tendon reflexes were intact. He had good fine motor control. 
Active and passive range of motion was restricted at his shoulders, Achilles tendons, elbows, knees, and jaw. He walked 
on his toes with a stiff, shuffling gait with almost no flexion at the knees or hips appreciated (Suppl. Video 1). Due to 
restricted movement at these joints, he could not reach his arms above his head. He had excessive thoracic kyphosis, with 
a minimal scoliosis, and rigidity of the lower spine (Fig. 1 A and B). He had short stature with height below the 5th 
percentile, weight along the 10th percentile and head circumference along the 50th percentile.  
He had a history of inappropriate sweating and was reported to be prone to “overheating” easily, particularly at 
night during sleep. His muscle stiffness was reported to exacerbate with movement and fatigue and improve with 
applying warm water to his muscles. He had a history of dysphagia and evidence of silent aspiration of liquids on 
videofluoroscopy.  He also had a history of frequent episodesof bronchiolitis.  He had been diagnosed with restrictive 
lung disease and uses a Cough Assist device to help improve expiratory function. A sleep study revealed evidence of 
hypoventilation. He has been advised to use nighttime non-invasive ventilation (NIV) in the form of bilevel positive 
airway pressure (BiPAP), but he could not tolerate the BiPAP mask.  After the time of our examination, he received two 
courses of Botulinum toxin injections to the hamstrings and pectoral muscles in an effort to improve his range of motion, 
and he was able to reach his arms above his head and walk with more fluidity by 5 years of age. Diagnostic testing 
performed on P1 included an electromyography (EMG) at age 6 months of age, which was interpreted as being 
myopathic with denervating features. Continuous motor unit activity in the form of myotonia and myokymia were not 
observed.   
 Patient 2 (P2) is a three year-old female. The pregnancy was notable for polyhydramnios and decreased fetal 
movement. She was born at term and presented with severe, generalized muscle stiffness immediately after birth. Flexion 
muscle contractures were present in all large joints, which reportedly resulted in an inability for active or passive 
movements. Apparent involvement of the respiratory muscles contributed to recurrent episodes of apnea that led to the 
need for invasive ventilation with high inspiratory pressures (up to 40 cm H2O). Treatment with carbamazepine, 
benzodiazepines, and baclofen reportedly provided no substantial benefit.  Due to continuing ventilatory dependency, a 
tracheostomy was placed. She also had a percutaneous gastrostomy tube placed for feeding (Fig. 1C). She was 
discharged from the hospital at the age of five months. At the current age of 3 years, she remains fully ventilator-
dependent with high inspiratory pressures (up to 25 cm H2O). On examination, she had normal eye movements, appeared 
mentally alert. Muscle tone was markedly increased with absent deep tendon reflexes. She demonstrated the ability to 
use a standing frame, but had difficulty sitting due to apparent hyperactivity of her hip extensors.  
Muscle tone reportedly reduced slightly after intramuscular injections of Botulinum toxin, and some limited 
voluntary movements were appreciated. She has started to use an assistive communication device.  Extensive diagnostic 
evaluations including brain magnetic resonance imaging (MRI), electroencephalography (EEG), and metabolic screening 
did not reveal any abnormalities. Serum creatine kinase (CK) levels varied between 200 and 1,000 U/L. EMG did not 
show evidence to myotonia or myokymia. Muscle ultrasound depicted markedly increased echogenicity of all muscles 
imaged but no evidence of muscle atrophy.  
 
Exome analysis identified two novel de novo glutamic acid residue deletions in Tpm3.12.  
Whole exome sequencing of P1 and both biological parents followed by variant filtering for call quality and 
rarity yielded a heterozygous c.673-675delGAA (p.Glu224del, ΔE224) TPM3 variant (reference NM_152263.3). Due to 
phenotypic similarity noted between P1 and P2, this region was Sanger sequenced in P2, revealing a heterozygous 3 base 
pair deletion c.657_659delAGA (p.Glu218del, ΔE218), resulting in the deletion of glutamic acid at amino acid 218 (Fig. 
2A and B). Parental segregation studies for P1 and P2 were negative: the mutation was de novo in both patients. Neither 
mutation had been previously reported and neitherwere present in dbSNP, NHLBI EVS, Exac Browser or GEM.app.16 
Both mutations are located in highly conserved regions of TPM3 (Fig. 2C and D).  
 
Tpm3.12 ΔE218 and ΔE224 muscle biopsies did not show typical tropomyosin-pathology.  
Muscle biopsy of P1 was performed at age 17 months and was mildly myopathic in appearance without specific 
features. There was mild variation in fiber size and a mild type I fiber predominance (Fig. 3 A and E). NADH staining 
demonstrated irregular staining in some fibers resulting in some areas of clearing (Fig. G). Modified Gömöri trichrome 
stain demonstrated irregularities of the myofibrillar apparatus. There was no evidence of clear nemaline rods or a pattern 
consistent with congenital fiber-type disproportion (CFTD) (Fig. 3C, E and G). There was ultrastructural evidence of 
accumulation of mitochondria, increased lipid storage and Z-line streaming and broadening, which was focal, occurring 
in rare fibers, and spanning up to 6-7 sarcomeres maximally, seen on electron microscopy along with some sarcolemmal 
folding as a result of fiber atrophy (EM) (Fig. 3I).  
Muscle biopsy of P2 was performed at age 3 weeks and demonstrated mild myopathic features. Findings 
included mild variation in fiber size and some rare basophilic fibers with centrally placed nuclei (Fig. 3B). There was 
mild type II fiber predominance seen on ATPase and NADH staining but no fiber-type grouping (Fig. 3F and H). 
Structures resembling minirods were identified on EM as well as some Z-band broadening in atrophic fibers (Fig. 3J). 
While clearly formed nemaline rods were not seen on modified Gömöri trichrome stain or EM, mini “miliary” rods were 
seen in small atrophic fibers on both modified Gömöri trichrome stain and on EM (Fig. 3D and J).  
 
Increased Ca2+-sensitivity for Tpm3.12 ΔE218 and ΔE224 by in vitro motility assay.  
 Using the in vitro motility assay, the movement of synthetic thin filaments containing recombinant wild type or 
mutant tropomyosin (Tpm3.12 ΔE218 and ΔE224) was compared over a range of Ca2+ concentrations. This assay 
measures two parameters that are Ca2+-regulated: fraction of filaments motile and sliding speed of the filaments. Ca2+ 
increased the fraction motile from 2% to 90% and the sliding speed from 1.3 to 4 µm/sec. The EC50 and Hill coefficient 
(nH) were determined by fitting the Hill equation to the Ca2+-activation curves. The mutations affected both the fraction 
motile and the sliding speed of the filaments in a similar way. Thin filaments reconstituted with mutant tropomyosins 
showed a higher Ca2+-sensitivity for both the fraction motile and the sliding speed; representative Ca2+ activation curves 
are shown in Figure 4. ΔE218 led to a 2 ½ -fold increase in Ca2+-sensitivity (EC50 ratio ΔΕ218/WT = 0.40 ± 0.07, p = 
0.004, n=4) for the fraction motile and a two-fold increase for the sliding speed (EC50 ratio ΔΕ218/WT = 0.48 ± 0.12, p = 
0.02, n=4). ΔΕ224 also showed an increase in Ca2+-sensitivity in both the fraction motile and the sliding speed parameter 
by 2.2 and 3.0-fold respectively (EC50 ratio ΔΕ224/WT for fraction motile = 0.46 ± 0.09, p = 0.01, n=4 EC50 ratio 
ΔΕ224/WT for sliding speed = 0.33 ± 0.08, p = 0.004, n=4), indicating that both mutations cause a gain of function. 
There was no significant difference in the maximum fraction motile, maximum sliding speed or Hill coefficient between 
either of the mutants and the wild type thin filaments. 
  
ΔE218 and ΔE224 permeabilized myofibers showed decreased maximum force generation and ΔE218 showed 
increased Ca2+-sensitivity with reduced cross-bridge cycling kinetics.   
Contractile properties of permeabilized myofibers isolated from biopsies from P1 and P2 (ΔE224 and ΔE218) 
were measured. The maximal active tension in ΔE218 (31 ± 5) and ΔE224 (35 ± 2) permeabilized myofibers showed a 
significant decrease in maximum force generation compared to controls (95 ± 14) (Fig. 5A). The Ca2+ sensitivity of force 
generation in ΔE224 (5.94 ± 0.02) was increased compared to control fibers (5.81 ± 0.02) (Fig. 5B and C). The 
maximum force a muscle fiber can generate is dependent on the rate of cross-bridge cycling kinetics. The rate constant of 
force redevelopment (Ktr) is a widely used parameter of cross-bridge cycling kinetics, reflecting both cross-bridge 
attachment and detachment. Analysis showed that cross-bridge cycling kinetics are reduced in Tpm3.12 ΔE224 (6.1 ± 1) 
compared to control myofibers (9.8 ± 1) (Fig. 5D) while maximal active tension over active stiffness, a reflection of the 
force per cross-bridge, was not altered between Tpm3.12 ΔE224 (2.2 ± 0.1) and control fibers (2.2 ± 0.1) (Fig. 5E). 
Unfortunately, due to technical limitations caused by lower quality and quantity of the biopsy, we could not measure 
cross-bridge cycling kinetics and force per cross-bridge in Tpm3.12 ΔE218.  
As the contractile performance of myofibers is dependent on the myosin heavy chain (MHC) isoform 
composition, the presence of MHC isoforms was determined. No significant changes between control myofibers (27 ± 
6% slow MHC and 73 ± 6% fast MHC) and ΔE218 (30 ± 5% slow MHC and 66 ± 6% fast MHC) or ΔE224 (20 ± 7% 
slow MHC and 80 ± 7% fast MHC) were found. Therefore, the changes observed in contractile performance between 
control and patient myofibers were not influenced by changes in myosin heavy isoform composition, and are more likely 
due to the specific mutations.  
 
 
 
DISCUSSION  
Muscle fiber based stiffness, in the absence of clinically detectable weakness, is a rare manifestation of 
congenital muscle disease. It was originally reported in Canadian aboriginal patients with a fatal condition characterized 
by progressive muscle stiffness and respiratory insufficiency15 due to recessive mutations in CRYAB. CRYAB codes 
forthe small chaperone αβ-crystalline; however, the mechanism responsible for the muscle stiffness remains unclear. 
Additionally, a specific de novo mutation in ACTA1 was found in a newborn with congenital episodic stiffness, 
hypertrophic muscles and nemaline rod muscle pathology.14 Our report is the first to demonstrate specific TPM3 
deletions as the cause of a novel phenotypic manifestation of marked and generalized congenital muscle stiffness. This 
phenotype is notable for an absence of muscle weakness in combination with muscle stiffness, so severe that it can result 
in early ventilatory failure, likely due to an inability of respiratory muscle relaxation, as evidenced by the high 
inspiratory pressures required during mechanical ventilation in P2.   
 The muscle thin filament is a cooperative-allosteric system. Its basic unit consists of a backbone of actin 
monomers, the troponin-tropomyosin complex and nebulin.24 Muscle contraction is regulated by Ca2+ via its release and 
reuptake from the sarcoplasmic reticulum. Ca2+ binding to troponin C on the thin filaments of muscle results in switching 
contraction from the “off” to the “on” state by causing a sideward shift of the actin-binding tropomyosin dimer, exposing 
the myosin binding site on the actin filament.30–32 Tropomyosins thus play a vital role in transmitting the Ca2+ signal 
from the troponin to the actin myosin binding site.  Mutations in TPM3 (coding for Tpm3.12) are an established 
molecular cause of a clinically and histopathologically heterogeneous group of myopathies, characterized by progressive 
weakness and by variable but characteristic findings on muscle pathology including nemaline rods, CFTD or cap-like 
structures. The phenotype associated with Tpm3.12 ∆E218 and ∆E224, withits congenital stiffness resulting from 
marked muscle hypercontractility, is significantly different from these known manifestation of TPM3-related disease. 
Muscle biopsies analysis did not reveal the typical muscle pathology seen in tropomyosin-related disease, including clear 
nemaline rods, although small rod-like structures (“miliary rods”) were seen in atrophic fibers of P1. We also found 
evidence of myofiber damage histologically, likely due to the permanently hypercontracted state of the muscle fibers, 
consistent with increased CK values. Six TPM2 and one TPM3 mutation that result in increased Ca2+-sensitivity have 
been reported in patients with only moderately progressive contractures and myopathic weakness.11,12,33In contrast, our 
patients present with a distinctive andconsiderably more severe congenital hypercontractile phenotype with generalized 
muscle stiffness leading to severe respiratory failure in the neonatal period in one case, which represents a novel 
phenotype for tropomyosin-related disease. 
Mutations in tropomyosin or actin that produce a hypercontractile phenotype may destabilize the “switched off” 
state, shifting the equilibrium in favor of the “switched on” state of actin-tropomyosin which allows for myosin binding, 
thereby increasing Ca2+-sensitivity and, in one case, increasing maximum force generated and cross bridge cycling 
rate.11,14,34,35 The finding that the Tpm3.12 ∆E218 and ∆E224 mutations introduced into recombinantly expressed 
tropomyosin resulted in increased Ca2+-sensitivity in the in vitro motility assay (Fig. 4), and that the Tpm3.12 ∆E224 
biopsy has increased Ca2+-sensitivity of force production (Fig. 5) is compatible with this mechanism as the basis of the 
hypercontractile phenotype.    
The hypercontractile phenotype associated with these Tpm3.12 mutations also conforms  to the predictions 
made by Marston et al.22 on biophysical grounds (Fig. 6), which we now confirm clinically as well as in vitro. The 
atomic resolution structure of tropomyosin-bound actin shows that tropomyosin makes contact with actin at only two 
points: with actin Asp25 and with a cluster of basic amino acids actin K326, K328 and R147.36 Tropomyosin has a 
seven-fold repeated structure corresponding to seven actin-binding interactions. Three Tpm2.2 mutations and the 
Tpm3.12 mutation K169E were shown to destabilize the interaction with actin Asp25, based on energy landscape 
calculations, and increase Ca2+-sensitivity in in vitro motility assay, consistent with gain of contractile function.22,37 More 
importantly, two Tpm2.2 mutations, ∆E139 and E181K, destabilize the interaction with the actin K326, K328, and R147 
cluster. All of these mutations involve a charge loss or reversal in a motif of two basic or acidic amino acids. There are 
nine such motifs in all tropomyosin isoforms. Mutations have been described in myopathy patients with increased in 
vitro Ca2+-sensitivity for six of the nine motifs (five in Tpm2.2 and one in Tpm3.12, three of which were associated with 
a phenotype of arthrogryposis or some signs of stiffness or contractures in addition to weakness). The remaining three 
motifs are at 218-219, 224-224 (EE), and 257-258 (ED) in either tropomyosin.22 Thus, the “stiff” patients’ mutations 
reported here are in the first two of these three remaining domains, which were predicted to result in a hypercontractile 
state. It is striking that the hypercontractile consequences in our cases are clinically more pronounced compared to the 
manifestations of other tropomyosin mutations previously reported.  Notably, most of the mutations tested in vitro and 
found to display increased Ca2+-sensitivity are located adjacent to the tropomyosin amino acid that interacts with actin 
rather than at the site itself.22 This also applies to Tpm3.12 E218 and E224, which do not interact with actin, whilst 
neighboring Tpm3.12 E219 and E223 interact directly with the actin K326, K328, and R147 cluster (Fig. 6). In light of 
the structural analysis modeling of these physical interactions, it is significant that the actin K326N mutation at the 
cognate site in actin itself was the first “stiff” patient mutation reported in a thin filament protein.14,22,38 The degree of 
stiffness seen in that patient appeared similar to our observation.14 
The in vitro sliding data obtained with mutant protein provide the crucial link to understanding the clinical 
hypercontractile phenotype; however, the consequences of the mutation on the entire thin filament and contractile fiber 
show additional complexities.  Notably, the skinned fiber preparation had decreased maximal active tension resulting in a 
decrease in maximal force generation, while the force per cross bridge was not altered. This raises the possibility that the 
cycling of cross bridges back into the “off” state is impaired. The observed reduction in rate constant of force 
redevelopment, which indicates a reduced effectiveness of cross bridge cycling, could explain the impaired force 
generation capacity of the muscle. Muscle fibers from P1 (∆E224) generated a higher relative force at the same Ca2+ 
concentration, which may therefore compensate for the loss of maximal force-generating capacity. Since there was no 
evidence of weakness in the patients (at the time of examination), we surmise that the hypercontractility at submaximal 
calcium concentrations is so overwhelming that any decrease in maximal force does not come to bear on the phenotype. 
The continuous cellular stress of the hypercontractility of the muscle may cause future muscle damage and breakdown in 
our patients, possibly resulting in weakness and findings of tropomyosin muscle pathology over time. That this is indeed 
occurring is suggested by the CK elevations and also by the markedly abnormal muscle ultrasound findings in P2.  
 The question remains as to why the stiffness phenotype in our patients is significantly more severe and 
generalized compared to the best characterized gain of function mutation in Tpm2.2, the ΔK7 deletion, identified in 
patients with progressive, early-onset contractures without clear muscle weakness in childhood but with some stiffness 
noted in one 14-year-old boy.11 Tpm2.2 is expressed in both fast and slow-twitch fibers. Increased Ca2+-sensitivity of 
force generation has also been observed in patients with distal arthrogryposis caused by mutations in troponin I (TNNI2) 
and troponin T3 (TNNT3), encoding for contractileapparatus proteins specific to fast-twitch fibers.40 Contractures of the 
distal muscles, which are predominantly fast-twitch fibers, typically develop prenatally but have little to no progression 
over time with relative normal proximal muscle strength and histology.41 The generalized and more severe congenital 
stiffness observed in the Tpm3.12 ∆E218 and ∆E224 patients may thus be partially related to the expression pattern, with 
Tpm3.12 being the most relevant tropomyosin for all slow-twitch fibers.  
Finally, we considered how the molecular mechanisms reported here could inform a rational therapeutic 
approach to these patients. P1 showed improvement with Botulinum toxin injections leading to increased range of 
motion, improved gait, and increased jaw mobility with enhanced speech production. Decreased neuromuscular 
transmission from the Botulinum application would lead to less activation of excitation-contraction coupling, likely 
taking the edge off the baseline hypercontractility associated with the underlying TPM3 mutation. Given the growing 
amount of literature supporting changed Ca2+-sensitivity of the actin-tropomyosin complex as a mechanism for muscle 
disease, future therapeutic strategies may involve reducing the release of Ca2+ at the sarcomere. An alternative approach 
would be to desensitize the thin filament to Ca2+.  In cases of decreased Ca2+-sensitivity, compounds that act as Ca2+ 
sensitizers, which are under active development in the neuromuscular and heart failure field may be utilised.40,41 The 
latter type of approach would likely be detrimental in the patients reported here.  
In conclusion, in this study we identified two patients with a marked congenital hypercontractile 
phenotype caused by dominantly acting de novo mutations in Tpm3.12, ΔE218 and ΔE224, representing the 
most severe tropomyosin-related hypercontractile phenotype recognized to date. Our experiments confirm a 
mechanism of increased Ca2+-sensitivity by which Tpm3.12 mutant muscle fibers contract at lower Ca2+ 
concentrations compared to wild type fibers. Our data lend in vivo and in vitro support to the conclusion that the 
increased Ca2+-sensitivity observed for both ΔE218 and ΔE224 results from a destabilization of the “off” state 
of the thin filament, resulting in excessively sensitized excitation-contraction coupling of the contractile 
apparatus, as previously predicted for ΔE218 on theoretical biophysical grounds. Mutations in tropomyosin, 
specifically in TPM3, should therefore be considered when evaluating a patient with congenital-onset muscle 
stiffness.  
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Table 1: Clinical details of P1 and P2.   
 Patient 1 (P1) Patient 2 (P2) 
Sex/age (years) Male/4 Female/3 
Tpm3.12 mutation ΔE224 ΔE218   
Presentation  
Decreased fetal movements. At birth: stiffness with 
arthrogryposis multiplex congenital, right clubfoot, 
bilateral hand fisting, inguinal hernia,bilateral hip 
dysplasia, and knee contractures.  
At birth: pronounced generalized stiffness, 
limited to absent movement, including the 
thoracic muscles requiring ventilation, hip 
dysplasia, umbilical hernia, left inguinal hernia. 
In infancy: recurrent hypoxic crises.  
Dysmorphic 
features 
Relative macrocephaly, short stature, and thin habitus. 
Prominent forehead, small mouth, short neck, and stiff 
face. 
Retrognathia, micrognathia, and short neck.  
Cognition Normal Normal 
Clinical features 
Kyphoscoliosis with lower spinal rigidity. Mild head 
lag, no slip-through, variable tone distally. Multiple 
bilateral contractures: shoulders, wrists with ulnar 
deviation, finger flexors, jaw, hip flexion, knee flexion, 
and heel cords. Prominent paraspinous muscles. Fine 
tremor. Reflexes present. Temperature dysregulation.  
Pronounced muscle hypertonia.  Kyphosis. 
Limited passive range of motion. Thoracic 
rigidity. Tracheostomy, ventilator and feeding 
tube dependent. She has a bladder catheter. 
Profuse sweating when excited.  
Motor function & 
strength  
Stiff gait marked by hip flexion, thoracic kyphosis, and 
flexion at the knees. Improvement over time. Strong 
bilateral grasp. No weakness.  
Limited to absent movement. Unable to sit or 
roll.   
Respiration 
Neonatal transient hypoxemia. Increased respiratory 
rate and occasional grunting. Frequent respiratory 
infections. Hypoxemia and obstructive sleep apnea 
requiring supplemental oxygen. 
Recurrent hypoxic crises in infancy. 
Tracheostomy and ventilator dependency. 
EMG 
Suggestive of a generalized myopathy with denervating 
features. No myotonia or myokymia observed.  
No evidence of spontaneous activity or 
myotonia.  
NCS 
Sensory responses of the right median and sural nerves 
were normal. Motor NCS of the right median nerve 
showed normal distal latency, moderate reduction in 
response amplitude and normal conduction velocity. 
Motor NCS of the right peroneal nerve showed normal 
distal latency, severe reduction in response amplitude, 
and normal conduction velocity.  
Not performed.  
Other 
CK: 205 U/L. Normal: EEG, brain MRI, and Echo. 
Negative: ACTA1, MYH3, TPM2, HSPG2, TNNT3, 
TNNI2, FKRP, CRYAB, and microarray.  
CK between 200-1,000 U/L. Osteopenia, 
shortened phalanges, and clinodactyly on X-ray. 
Normal: brain MRI, EEG and metabolic 
screening. Negative ACTA1 and CRYAB. 
Increased echogenicity on muscle ultrasound.   
FIGURE LEGENDS 
Figure 1.  
(A and B). 4 year old male (P1) with relative macrocephaly compared to his short stature and thin habitus. He has a 
prominent forehead, small mouth, short neck and stiff face. His shoulders are anteriorly rotated with decreased lumbar 
lordosis and increased kyphosis and he has bilateral elbow and knee contractures. He has flat feet that are turned 
outwards, external hip rotation and a barrel chest with wide spaced nipples. (C). 3-year-old female (P2) with pronounced 
muscle stiffness. She has bilateral contractures of elbows, knees and ankles. She is ventilated with tracheostomy and has 
a feeding tube.  
Figure 2.   
Sequence chromatogram of P1 & P2 identifying a glutamic acid deletion in Tpm3.12. (A and B). Schematic of known 
mutations in TPM3 along with their disease phenotypes (C). Illustration of amino acid homology of TPM3, P1, P2 as 
well as for TPM1, 2 & 4 (D). 
Figure 3.  
Muscle biopsy of P1 at age 17 months (left) and P2 at age 22 days (right). H&E shows variability in fiber size with 
increased perimysial and endomysial fibrosis in P1 (A) and P2 (B). There are some rare basophilic fibers in P2 (B) with 
centrally placed nuclei (green arrow). Trichrome staining does not show inclusions suggestive of nemaline rods or 
vacuoles in P1 (C) while P2 showed “miliary” rod-like inclusions in some of the atrophic fibers (D). There is variation in 
fiber size of both fiber types on ATPase 9 in P1 (E) and ATPase 10.5 in P2 (F) there is mild type 1 predominance in P1 
and mild type 2 fiber predominance in P2. NADH in P1 (G) and P2 (H) show a decrease in staining in the periphery of 
some of the darker (type I) fibers, there is mitochondrial aggregation and contracted fibers (green arrow). EM of P1 
shows and atrophic muscle fiber with Z-disk streaming (green arrow) and sarcolemmal folds (blue arrow) (I).  EM of P2 
also shows Z-band broadening in an atrophic fiber (red arrow). There are some “miliary” rods (blue arrow). No clear 
nemaline rods were seen (J). 
Figure 4.  
Ca
2+
 control of in vitro motility.  Representative Ca
2+
-activation curves; ∆E218 left and ∆E224 on right compared with 
wild-type control.  Thin filaments were assembled using baculovirus expressed Tpm3.12, rabbit skeletal muscle actin 
and rabbit skeletal muscle troponin.  Thin filament movement over immobilized HMM was tracked and analyzed over a 
range of Ca
2+ 
concentrations.  Solid lines, control; dotted lines mutant tropomyosin. Error bars are SD for 4 
measurements of motility in the same motility cell. The curves are the fits of the data to the Hill equation; sliding speed 
(top) and fraction of filaments motile parameters (bottom). Four separate Ca
2+
-curves were determined for each 
mutation. For WT and ∆E218 EC
50
 for fraction motile were 0.20±0.06 and 0.07±0.02 respectively, for sliding speed 
0.22±0.08 and 0.08±0.01 respectively.  For WT and ∆E224 EC
50
 for fraction motile were 0.19±0.05 and 0.07±0.021 
respectively, for sliding speed 0.30±0.08 and 0.09±0.02 respectively.     
 
Figure5.   
A significant decrease in maximum force generation was seen in single fiber myofibres from Tpm3.12 ∆E224 & ∆E218 
compared to controls (A). The Ca
2+
 sensitivity of force generation was increased in ∆E224 compared to controls and 
∆E218 (B and C). Additionally there is reduced cross-bridge cycling kinetics in Tpm3.12 ∆E224 (D) while the active 
stiffness was not altered between Tpm3.12 ∆E224 and control (E).  
Figure 6. 
Location of gain-of function mutations in tropomyosin isoforms Tpm2.2 and Tpm3.12.  The amino acids predicted to 
interact with actin are circled (A). Structure of the F-actin-tropomyosin complex determined by Li et al (2011).  Surface 
rendering using PyMol.  Actin K326, K328 and R147 are shown in different shades of blue and tropomyosin 218,219 
223 and 224 are shown in magenta (B). The interface of tropomyosin period 6 with actin.  Actin K326, K328 and R147 
are shown in different shades of blue, E214 and E224 in red and 219 and 223 are shown in pink.  Actin is represented by 
surface rendering; the secondary structure of tropomyosin backbone (coiled-coil alpha helix) is shown with the side 
chains in line notation (C). 
Supplemental Video 1. 
Gait of P1 at age 4 years. He walks with a stiff, shuffling gait, on his toes, with almost no flexion at the knees or hips.  
